Relapsed or Refractory

Daratumumab, Bortezomib, and Dexamethasone with or without Venetoclax in Treating Patients with Relapsed or Refractory Multiple Myeloma


Physician and Research Staff Educational Materials

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

    • Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study.

Information and Assistance from the National Cancer Institute

    • Locations and other information
    • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail. ID: NCT03701321

Return to Home Page | Review Other Active Trials